The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...

NICE’s decisions for both drugs are not final and are pending more evidence. Credit: Art_Photo via Shutterstock. · Clinical ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...

The UK’s AstraZeneca, which is working on an oral GLP-1, also views the drugs as part of a combination strategy. In other ...

Analyst Alec Stranahan of Bank of America Securities maintained a Hold rating on Alector (ALEC – Research Report), retaining the price ...

Global Gene Therapy in CNS Disorder IndustryThe global gene therapy market for central nervous system (CNS) disorders is set ...

Southwest Airlines settles with activist to end proxy fight, Novo Nordisk’s Ozempic might reduce Alzheimer’s risk, and more ...

Despite a double-digit pullback from July’s peaks, CRBP is already up 174% so far in 2024, crushing the broader market’s ...